// App-Quantinova.ai

P839 : PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN SHOW IMPROVEMENTS IN D-DIMER NORMALIZATION AND DECREASE IN INCIDENCE OF THROMBOSIS

Researchers

Presenter

  • Ilene Weitz

Principal Investigators

  • Mohammed Al-Adhami

  • Jinny Min

  • Michael Yeh

  • Jessica Savage

  • David Dingli

Medical Centers

  • Mayo Clinic–Rochester

  • Hematology,Mayo Clinic,Rochester, MN,Vereinigte Staaten

  • Jane Anne Nohl Division of Hematology,Keck-USC School of Medicine,Los Angeles, CA,United States

  • Jane Anne Nohl Division of Hemat

  • Swedish Orphan Biovitrum AB, Stockholm, Sweden

  • Hematology,Mayo Clinic,Rochester, MN,États-unis

  • Swedish Orphan Biovitrum AB, Stockholm, Sweden

  • Apellis Pharmaceuticals, Waltham,Waltham,États-unis

  • Swedish Orphan Biovitrum AB, Stockholm, Sweden

  • Swedish Orphan Biovitrum AB, Stockholm, Sweden

  • Swedish Orphan Biovitrum AB, Stockholm, Sweden

  • Swedish Orphan Biovitrum AB, Stockholm, Sweden

  • Jane Anne Nohl Division of Hematology,Keck-USC School of Medicine,Los Angeles, CA,United States

  • Mayo Clinic,Rochester,Stati Uniti

  • Apellis Pharmaceuticals

  • Mayo Clinic, Rochester, United States

  • Apellis Pharmaceuticals, Inc.,Waltham,Estados Unidos

  • Jane Anne Nohl Division of Hematology,Keck-USC School of Medicine,Los Angeles, CA,United States

  • Jane Anne Nohl Division of Hematology,Keck-USC School of Medicine,Los Angeles, CA,United States

  • Apellis Pharmaceuticals, Waltham,Waltham,États-unis

  • Swedish Orphan Biovitrum AB, Stockholm, Sweden

  • Swedish Orphan Biovitrum AB, Stockholm, Sweden

  • Mayo Clinic,Rochester,Estados Unidos

  • Apellis Pharmaceuticals, Waltham,Waltham,Vereinigte Staaten

  • Apellis Pharmaceuticals, Waltham,Waltham,Vereinigte Staaten

  • Swedish Orphan Biovitrum AB,Stockholm,Швеция

  • Apellis Pharmaceuticals, Inc.,Waltham,United States

  • Hematology,Mayo Clinic,Rochester, MN,Vereinigte Staaten

Locations

  • United States

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Venous thrombosis

Biomarkers

  • D-dimer

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT03500549

  • NCT04085601

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved